Key terms
About XCUR
Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. Its product pipeline include Cavrotolimod (AST-008) and XCUR-FXN. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in June 2011 and is headquartered in Skokie, IL.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest XCUR news
Apr 22
4:02pm ET
Exicure receives Nasdaq delinquency notice
Feb 09
11:12am ET
Biotech Alert: Searches spiking for these stocks today
Feb 08
11:40am ET
Biotech Alert: Searches spiking for these stocks today
Feb 06
4:48am ET
Exicure Inc Announces Licensing Patents for Therapeutic Advancement
Feb 05
4:02pm ET
Exicure, Bluejay Therapeutics enter into patent license pact
No recent press releases are available for XCUR
XCUR Financials
Key terms
Ad Feedback
XCUR Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
XCUR Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range